Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
8.06
+0.43 (5.64%)
Nov 11, 2026, 4:00 PM EST - Market closed
Eupraxia Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Eupraxia Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $16.68. The average 1-year stock price forecast is 106.95% higher than the current stock price, while the lowest is $14 (+73.70%) and the highest is $25 (+210.17%).
Price Target: $16.68 (+106.95%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Eupraxia Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 12 | 12 | 12 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $19 | Buy | Maintains | $19 | +135.73% | Nov 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $11 → $16 | Buy | Reiterates | $11 → $16 | +98.51% | Nov 11, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $17 | Buy | Maintains | $17 | +110.92% | Nov 11, 2026 |
| RBC Capital | RBC Capital | Buy Initiates $14 | Buy | Initiates | $14 | +73.70% | Nov 9, 2026 |
| Wedbush | Wedbush | Buy Maintains $17 | Buy | Maintains | $17 | +110.92% | Oct 1, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
553.55K
EPS This Year
-0.97
from -0.98
EPS Next Year
-1.05
from -0.97
EPS and Forward PE are based on non-GAAP adjusted numbers.